Navidea Biopharma Says PDUFA Goal Date for Lymphoseek April 30, 2013 - Navidea Biopharmaceutical (OTC:NAVB)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical companyfocused on precision diagnostic radiopharmaceuticals, announced today that theU.S. Food and Drug Administration (FDA) has accepted the filing of theCompany's October 30, 2012 resubmission of its New Drug Application (NDA) forLymphoseek (Technetium Tc 99m Tilmanocept) Injection. In its acknowledgment,FDA noted that it considers the filing a complete, class 2 response to itsSeptember 10, 2012 action letter and has set a Prescription Drug User Fee Act(PDUFA) goal date of April 30, 2013. Lymphoseek ^ is a novel,receptor-targeted, small-molecule, investigational radiopharmaceutical used inlymphatic mapping procedures that are performed to help stage cancer.Lymphoseek is designed to identify the lymph nodes that drain from a primarytumor, which have the highest probability of harboring cancer.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!